Discerning the clinical relevance of biomarkers in early stage breast cancer

Tarah J. Ballinger, Nawal Kassem, Fei Shen, Guanglong Jiang, Mary Lou Smith, Elda Railey, John Howell, Carol B. White, Bryan Schneider

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Prior data suggest that breast cancer patients accept significant toxicity for small benefit. It is unclear whether personalized estimations of risk or benefit likelihood that could be provided by biomarkers alter treatment decisions in the curative setting. Methods: A choice-based conjoint (CBC) survey was conducted in 417 HER2-negative breast cancer patients who received chemotherapy in the curative setting. The survey presented pairs of treatment choices derived from common taxane- and anthracycline-based regimens, varying in degree of benefit by risk of recurrence and in toxicity profile, including peripheral neuropathy (PN) and congestive heart failure (CHF). Hypothetical biomarkers shifting benefit and toxicity risk were modeled to determine whether this knowledge alters choice. Previously identified biomarkers were evaluated using this model. Results: Based on CBC analysis, a non-anthracycline regimen was the most preferred. Patients with prior PN had a similar preference for a taxane regimen as those who were PN naïve, but more dramatically shifted preference away from taxanes when PN was described as severe/irreversible. When modeled after hypothetical biomarkers, as the likelihood of PN increased, the preference for taxane-containing regimens decreased; similarly, as the likelihood of CHF increased, the preference for anthracycline regimens decreased. When evaluating validated biomarkers for PN and CHF, this knowledge did alter regimen preference. Conclusions: Patients faced with multi-faceted decisions consider personal experience and perceived risk of recurrent disease. Biomarkers providing information on likelihood of toxicity risk do influence treatment choices, and patients may accept reduced benefit when faced with higher risk of toxicity in the curative setting.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalBreast Cancer Research and Treatment
DOIs
StateAccepted/In press - Apr 11 2017

Fingerprint

Peripheral Nervous System Diseases
Biomarkers
Breast Neoplasms
Heart Failure
Anthracyclines
Taxoids
Therapeutics
Recurrence
Drug Therapy
taxane

Keywords

  • Breast cancer
  • Congestive heart failure
  • Conjoint analysis
  • Genetic biomarker
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Discerning the clinical relevance of biomarkers in early stage breast cancer. / Ballinger, Tarah J.; Kassem, Nawal; Shen, Fei; Jiang, Guanglong; Smith, Mary Lou; Railey, Elda; Howell, John; White, Carol B.; Schneider, Bryan.

In: Breast Cancer Research and Treatment, 11.04.2017, p. 1-9.

Research output: Contribution to journalArticle

Ballinger, Tarah J. ; Kassem, Nawal ; Shen, Fei ; Jiang, Guanglong ; Smith, Mary Lou ; Railey, Elda ; Howell, John ; White, Carol B. ; Schneider, Bryan. / Discerning the clinical relevance of biomarkers in early stage breast cancer. In: Breast Cancer Research and Treatment. 2017 ; pp. 1-9.
@article{860471f887e041289487430a2105928d,
title = "Discerning the clinical relevance of biomarkers in early stage breast cancer",
abstract = "Purpose: Prior data suggest that breast cancer patients accept significant toxicity for small benefit. It is unclear whether personalized estimations of risk or benefit likelihood that could be provided by biomarkers alter treatment decisions in the curative setting. Methods: A choice-based conjoint (CBC) survey was conducted in 417 HER2-negative breast cancer patients who received chemotherapy in the curative setting. The survey presented pairs of treatment choices derived from common taxane- and anthracycline-based regimens, varying in degree of benefit by risk of recurrence and in toxicity profile, including peripheral neuropathy (PN) and congestive heart failure (CHF). Hypothetical biomarkers shifting benefit and toxicity risk were modeled to determine whether this knowledge alters choice. Previously identified biomarkers were evaluated using this model. Results: Based on CBC analysis, a non-anthracycline regimen was the most preferred. Patients with prior PN had a similar preference for a taxane regimen as those who were PN na{\"i}ve, but more dramatically shifted preference away from taxanes when PN was described as severe/irreversible. When modeled after hypothetical biomarkers, as the likelihood of PN increased, the preference for taxane-containing regimens decreased; similarly, as the likelihood of CHF increased, the preference for anthracycline regimens decreased. When evaluating validated biomarkers for PN and CHF, this knowledge did alter regimen preference. Conclusions: Patients faced with multi-faceted decisions consider personal experience and perceived risk of recurrent disease. Biomarkers providing information on likelihood of toxicity risk do influence treatment choices, and patients may accept reduced benefit when faced with higher risk of toxicity in the curative setting.",
keywords = "Breast cancer, Congestive heart failure, Conjoint analysis, Genetic biomarker, Peripheral neuropathy",
author = "Ballinger, {Tarah J.} and Nawal Kassem and Fei Shen and Guanglong Jiang and Smith, {Mary Lou} and Elda Railey and John Howell and White, {Carol B.} and Bryan Schneider",
year = "2017",
month = "4",
day = "11",
doi = "10.1007/s10549-017-4238-0",
language = "English (US)",
pages = "1--9",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",

}

TY - JOUR

T1 - Discerning the clinical relevance of biomarkers in early stage breast cancer

AU - Ballinger, Tarah J.

AU - Kassem, Nawal

AU - Shen, Fei

AU - Jiang, Guanglong

AU - Smith, Mary Lou

AU - Railey, Elda

AU - Howell, John

AU - White, Carol B.

AU - Schneider, Bryan

PY - 2017/4/11

Y1 - 2017/4/11

N2 - Purpose: Prior data suggest that breast cancer patients accept significant toxicity for small benefit. It is unclear whether personalized estimations of risk or benefit likelihood that could be provided by biomarkers alter treatment decisions in the curative setting. Methods: A choice-based conjoint (CBC) survey was conducted in 417 HER2-negative breast cancer patients who received chemotherapy in the curative setting. The survey presented pairs of treatment choices derived from common taxane- and anthracycline-based regimens, varying in degree of benefit by risk of recurrence and in toxicity profile, including peripheral neuropathy (PN) and congestive heart failure (CHF). Hypothetical biomarkers shifting benefit and toxicity risk were modeled to determine whether this knowledge alters choice. Previously identified biomarkers were evaluated using this model. Results: Based on CBC analysis, a non-anthracycline regimen was the most preferred. Patients with prior PN had a similar preference for a taxane regimen as those who were PN naïve, but more dramatically shifted preference away from taxanes when PN was described as severe/irreversible. When modeled after hypothetical biomarkers, as the likelihood of PN increased, the preference for taxane-containing regimens decreased; similarly, as the likelihood of CHF increased, the preference for anthracycline regimens decreased. When evaluating validated biomarkers for PN and CHF, this knowledge did alter regimen preference. Conclusions: Patients faced with multi-faceted decisions consider personal experience and perceived risk of recurrent disease. Biomarkers providing information on likelihood of toxicity risk do influence treatment choices, and patients may accept reduced benefit when faced with higher risk of toxicity in the curative setting.

AB - Purpose: Prior data suggest that breast cancer patients accept significant toxicity for small benefit. It is unclear whether personalized estimations of risk or benefit likelihood that could be provided by biomarkers alter treatment decisions in the curative setting. Methods: A choice-based conjoint (CBC) survey was conducted in 417 HER2-negative breast cancer patients who received chemotherapy in the curative setting. The survey presented pairs of treatment choices derived from common taxane- and anthracycline-based regimens, varying in degree of benefit by risk of recurrence and in toxicity profile, including peripheral neuropathy (PN) and congestive heart failure (CHF). Hypothetical biomarkers shifting benefit and toxicity risk were modeled to determine whether this knowledge alters choice. Previously identified biomarkers were evaluated using this model. Results: Based on CBC analysis, a non-anthracycline regimen was the most preferred. Patients with prior PN had a similar preference for a taxane regimen as those who were PN naïve, but more dramatically shifted preference away from taxanes when PN was described as severe/irreversible. When modeled after hypothetical biomarkers, as the likelihood of PN increased, the preference for taxane-containing regimens decreased; similarly, as the likelihood of CHF increased, the preference for anthracycline regimens decreased. When evaluating validated biomarkers for PN and CHF, this knowledge did alter regimen preference. Conclusions: Patients faced with multi-faceted decisions consider personal experience and perceived risk of recurrent disease. Biomarkers providing information on likelihood of toxicity risk do influence treatment choices, and patients may accept reduced benefit when faced with higher risk of toxicity in the curative setting.

KW - Breast cancer

KW - Congestive heart failure

KW - Conjoint analysis

KW - Genetic biomarker

KW - Peripheral neuropathy

UR - http://www.scopus.com/inward/record.url?scp=85017422323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017422323&partnerID=8YFLogxK

U2 - 10.1007/s10549-017-4238-0

DO - 10.1007/s10549-017-4238-0

M3 - Article

C2 - 28401365

AN - SCOPUS:85017422323

SP - 1

EP - 9

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

ER -